Nohla Therapeutics, a Seattle, WA-based developer of universal, off-the-shelf cell therapies for patients with hematologic malignances and other critical diseases, closed a $45m Series B financing.
The round was led by Fidelity Management and Research Company and Celgene Corporation (Nasdaq:CELG) which joined existing investors ARCH Venture Partners, 5AM Ventures, Alexandria Venture Investments and AML Biotech Partners.
The company intends to use the funds to complete the ongoing Phase 2 trials of its lead candidate, dilanubicel (NLA101), in allogeneic transplant and chemotherapy-induced myelosuppression, as well as support Phase 3 trial and commercial manufacturing needs, and to advance its novel cell-based therapy platform and pipeline.
Led by Katie Fanning, President and Chief Executive Officer, Nohla is a developer of off-the shelf cell therapies for the treatment of cancer and other critical diseases. The company’s lead product candidate, dilanubicel, is currently being evaluated in two ongoing Phase 2 trials for patients with hematologic malignancies undergoing a myeloablative allogeneic transplant, and acute myeloid leukemia (AML) patients with chemotherapy-induced myelosuppression following high-dose chemotherapy.
Nohla is also pursuing multiple preclinical and discovery programs in the areas of immune tolerance and other diseases.